Neuroimmunology and Neuro-Oncology Unit, National Institute of Neurology and Neurosurgery, 14269 Mexico City, DF, Mexico.
Biomed Res Int. 2013;2013:351031. doi: 10.1155/2013/351031. Epub 2013 Apr 18.
Glioblastoma multiforme (GBM) is one of the most deadly diseases that affect humans, and it is characterized by high resistance to chemotherapy and radiotherapy. Its median survival is only fourteen months, and this dramatic prognosis has stilled without changes during the last two decades; consequently GBM remains as an unsolved clinical problem. Therefore, alternative diagnostic and therapeutic approaches are needed for gliomas. Nanoparticles represent an innovative tool in research and therapies in GBM due to their capacity of self-assembly, small size, increased stability, biocompatibility, tumor-specific targeting using antibodies or ligands, encapsulation and delivery of antineoplastic drugs, and increasing the contact surface between cells and nanomaterials. The active targeting of nanoparticles through conjugation with cell surface markers could enhance the efficacy of nanoparticles for delivering several agents into the tumoral area while significantly reducing toxicity in living systems. Nanoparticles can exploit some biological pathways to achieve specific delivery to cellular and intracellular targets, including transport across the blood-brain barrier, which many anticancer drugs cannot bypass. This review addresses the advancements of nanoparticles in drug delivery, imaging, diagnosis, and therapy in gliomas. The mechanisms of action, potential effects, and therapeutic results of these systems and their future applications in GBM are discussed.
多形性胶质母细胞瘤(GBM)是影响人类的最致命疾病之一,其特征是对化疗和放疗具有高度耐药性。其中位生存期仅为 14 个月,在过去的二十年中,这种戏剧性的预后并没有改变;因此,GBM 仍然是一个未解决的临床问题。因此,需要替代的诊断和治疗方法来治疗神经胶质瘤。纳米颗粒因其自组装能力、小尺寸、增加的稳定性、生物相容性、使用抗体或配体对肿瘤的特异性靶向、包裹和输送抗肿瘤药物以及增加细胞与纳米材料之间的接触表面积,成为 GBM 研究和治疗的创新工具。通过与细胞表面标志物缀合对纳米颗粒进行主动靶向,可以增强纳米颗粒将几种药物递送至肿瘤区域的功效,同时显著降低生物系统中的毒性。纳米颗粒可以利用一些生物学途径来实现对细胞和细胞内靶标的特异性递送,包括穿过血脑屏障的转运,许多抗癌药物无法绕过血脑屏障。本文综述了纳米颗粒在神经胶质瘤的药物输送、成像、诊断和治疗方面的进展。讨论了这些系统的作用机制、潜在影响和治疗结果,以及它们在 GBM 中的未来应用。